O
ORIC
Oric Pharmaceuticals, Inc.
8.32
-0.14-1.65%After Hours: 8.48 +0.16 +1.92%19:58 05/22 EDT
OPEN/PREV CLOSE8.50/8.46
TODAY RANGE8.28-8.70
VOL795.22K
MARKET CAP861.27M
52 WEEK RANGE4.650-14.93
AVG VOL (3M)1.90M
% TURNOVER0.77%
TURNOVER--
P/E (TTM)-5.8157
% RANGE4.73%
EPS(TTM)-1.4306
P/E(FORWARD)-5.8352
P/B2.072
BVPS4.016
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP788.47M
SHARES OUTSTANDING103.52M
NEXT EARNINGS08/10-08/14
FREE FLOAT94.77M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·05/15 09:11
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
Dow Jones·05/05 16:04
Oric Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones·05/05 16:04
Oric Pharmaceuticals Price Target Cut to $16.00/Share From $17.00 by Citigroup
Benzinga·05/05 15:54
Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16
TipRanks·05/05 13:46
Oric Pharmaceuticals (ORIC) Initiated with a Buy at Wedbush
TipRanks·05/05 11:18
Guggenheim Remains a Buy on Oric Pharmaceuticals (ORIC)
TipRanks·05/05 11:18
Oric Pharmaceuticals (ORIC) Receives a Buy from Wells Fargo
TipRanks·05/05 10:39
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
Dow Jones·05/04 20:47
*Oric Pharmaceuticals Sees Funding Sufficient Into 2H28 >ORIC
TipRanks·05/04 20:44
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
Reuters·05/04 20:27
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs